Lilly’s New Weight-Loss Pill Foundayo Gets Off to a Slow Start
Lilly’s new weight-loss pill started slow, far behind Novo’s, but it’s too early to tell which drug will win.
/ 88 items
#LLY↓
Lilly Buys Kelonia for Up to $7 Billion to Make CAR-T Cancer Therapy Simple and Fast
Eli Lilly buys Kelonia to develop a simpler, one-shot cancer therapy that reprograms immune cells directly inside the body.
Lilly’s Foundayo Pill Launches Strong: 1,400 Prescriptions in Week 1
Eli Lilly’s new GLP-1 pill shows strong early demand, big weight loss benefits, and promising heart & diabetes results.
Novo Nordisk Teams Up with OpenAI: AI Supercharges the Fight Against Obesity
Novo Nordisk teams with OpenAI to use AI for faster drug discovery, production and sales, aiming to catch rivals like Eli Lilly.
AC Immune & Lilly Team Up Again to Stop Alzheimer’s with Brain-Targeting Drugs
AC Immune updates Eli Lilly deal to develop pill-based Tau drugs for Alzheimer’s, aiming to stop disease early with promising preclinical results.
FDA Tightens Rules on Copycat Ozempic and Wegovy – No More Routine Compounding
FDA limits copycat GLP-1 drugs; pharmacies can only make them during shortages. Original meds like Foundayo now safer & more available.